Meta-analysis of the efficacy and impact on cardiac function of sodium–glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients

Weidong Li,Xuanyang Shen,Meiqi Zhang,Wentao Tan,Xiaolu Jiang,Hongfu Wen,Yuan Shen

DOI: https://doi.org/10.1097/md.0000000000040409

IF: 1.6

2024-11-13

Medicine

Abstract:Heart failure (HF) is a common and severe cardiovascular disorder that has attracted considerable global attention due to its high incidence and substantial disability rates. [ 1 ] HF ranks as one of the leading causes of death worldwide, with millions of new cases diagnosed annually, primarily affecting the elderly population, especially those aged 65 and older. [ 2 ] HF exhibits a higher prevalence in males at a younger age, while females experience an increased risk after menopause. [ 3 ] Risk factors for HF encompass various elements, including coronary artery disease, hypertension, diabetes, myocardial disease, valvular heart disease, medications, among others. [ 4 , 5 ] HF results in the heart's inability to effectively pump blood, leading to insufficient oxygen and nutrient supply to the body, causing patients to frequently experience fatigue, shortness of breath, and weakness. This condition also leads to the accumulation of extracellular fluid in the body, causing edema and pulmonary congestion, which escalates the risk of respiratory distress. Additionally, HF patients may experience arrhythmias, increasing their susceptibility to stroke. [ 6 ] HF detrimentally affects renal function, leading to declining kidney function and fluid retention in patients. [ 7 ] As the disease progresses, HF causes damage to multiple organs and systems throughout the body, resulting in significant harm to the organism. [ 8 ] Hence, effective preventative measures and treatment modalities play a crucial role in addressing HF.

medicine, general & internal